New combo therapy trial offers hope for tough bladder cancers
NCT ID NCT07189793
Summary
This study is for adults with a high-risk type of bladder cancer that has not responded to or cannot tolerate the standard BCG treatment. It will compare a two-part treatment (an immunotherapy drug given through a vein plus two chemotherapy drugs placed directly into the bladder) against the immunotherapy drug alone. The main goals are to see if the combination is better at getting rid of cancer in the bladder lining and at preventing the cancer from coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for URINARY BLADDER NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.